Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dolutegravir plus Lamivudine in HIV with TDF Toxicity
NCT05493969Phase 4Not yet recruiting
- Start
- Aug 2022
- Primary completion
- Aug 2025
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of dolutegravir, lamivudine in human immunodeficiency virus infection (HIV). Planned start Aug 2022; status: not yet recruiting.
02
Drugs
dolutegravirlamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05493969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05493969.